Dataset Information
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Ontology highlight
ABSTRACT:
SUBMITTER: Laetsch TW
PROVIDER: S-EPMC5949072 | biostudies-literature | 2018 May
REPOSITORIES: biostudies-literature
Publications
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
The Lancet. Oncology 20180329 5
<h4>Background</h4>Gene fusions involving NTRK1, NTRK2, or NTRK3 (TRK fusions) are found in a broad range of paediatric and adult malignancies. Larotrectinib, a highly selective small-molecule inhibitor of the TRK kinases, had shown activity in preclinical models and in adults with tumours harbouring TRK fusions. This study aimed to assess the safety of larotrectinib in paediatric patients.<h4>Methods</h4>This multicentre, open-label, phase 1/2 study was done at eight sites in the USA and enroll ...[more]